Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations
- 1 November 2002
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 54 (11) , 1507-1514
- https://doi.org/10.1211/002235702199
Abstract
To be effective, herbal medicinal products are expected to meet comparable standards concerning the assessment of efficacy, safety and biopharmaceutical quality as chemically defined synthetic drugs as food supplements. However, these requirements are often not fulfilled, particularly regarding the characterization of biopharmaceutical properties such as in-vitro dissolution and in-vivo bioavailability. With respect to the relevance of biopharmaceutical quality of herbal medicinal products, two different Ginkgo biloba brands (test product: Ginkgo biloba capsules; reference product: Ginkgold) were analysed for dissolution rates and bioavailability of the most relevant active ingredients. Dissolution rates at pH 1 and 4.5 were determined according to the USP 23. The relative bioavailability of ginkgolide A, ginkgolide B and bilobalide was investigated after single oral administration of 120 mg Ginkgo biloba extract as tablets or capsules. Bioavailability data (area under the curve and peak concentration in plasma) were clearly different and did not show bioequivalence of test and reference products. The slow in-vitro dissolution of the test product resulted in a large decrease in bioavailability. These results indicate for the first time that the pharmaceutical properties of a herbal medicinal product have a significant impact on the rate and extent of drug absorption, and very likely on efficacy in humans.Keywords
This publication has 32 references indexed in Scilit:
- A 26-Week Analysis of a Double-Blind, Placebo-Controlled Trial of the Ginkgo biloba Extract EGb 761® in DementiaDementia and Geriatric Cognitive Disorders, 2000
- The ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by β‐amyloidEuropean Journal of Neuroscience, 2000
- Biopharmaceutical characterisation of herbal medicinal products: are in vivo studies necessary?European Journal of Drug Metabolism and Pharmacokinetics, 2000
- Bioavailability of Ginkgolides and Bilobalide from Extracts ofGinkgo bilobausing GC/MSPlanta Medica, 1999
- A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for DementiaJAMA, 1997
- In vivo regulation of peripheral-type benzodiazepine receptor and glucocorticoid synthesis by Ginkgo biloba extract EGb 761 and isolated ginkgolides.Endocrinology, 1996
- Proof of Efficacy of the Ginkgo Biloba Special Extract EGb 761 in Outpatients Suffering from Mild to Moderate Primary Degenerative Dementia of the Alzheimer Type or Multi-infarct DementiaPharmacopsychiatry, 1996
- What do commercial ginseng preparations contain?Published by Elsevier ,1994
- Ginkgo bilobaThe Lancet, 1992
- Parthenolide Content and Bioactivity of Feverfew (Tanacetum parthenium (L.) Schultz-Bip.). Estimation of Commercial and Authenticated Feverfew ProductsJournal of Pharmacy and Pharmacology, 1992